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Abstract
The Gleason score is an important parameter for clinical outcome in prostate cancer patients. Gleason score 8 is a
heterogeneous disease including Gleason score 3+ 5, 4+ 4, and 5+ 3 tumors, and encompasses a broad range of tumor
growth patterns. Our objective was to characterize individual growth patterns and identify prognostic parameters in Gleason
score 8 prostate cancer patients. We reviewed 1064 radical prostatectomy specimens, recorded individual Gleason 4 and 5
growth patterns as well as presence of intraductal carcinoma, and evaluated biochemical recurrence- and metastasis-free
survival. Gleason score 8 disease was identified in 140 (13%) patients, of whom 76 (54%) had Gleason score 3+ 5, 46
(33%) 4+ 4, and 18 (13%) 5+ 3 disease. Invasive cribriform and/or intraductal carcinoma (n= 87, 62%) was observed
more frequently in Gleason score 4+ 4 (93%) than 3+ 5 (47%; P < 0.001) and 5+ 3 (44%; P < 0.001) patients. Gleason
pattern 5 was present in 110 (79%) men: as single cells and/or cords in 99 (90%) and solid fields in 32 (29%) cases. Solid
field pattern 5 coexisted with cribriform architecture (23/32, 72%) more frequently than nonsolid pattern 5 cases (36/78,
46%, P= 0.02). In multivariable analysis including age, prostate-specific antigen, pT-stage, surgical margin status, and
lymph node metastases, presence of cribriform architecture was an independent parameter for biochemical recurrence-free
(hazard ratio (HR) 2.0, 95% confidence interval (CI) 1.0–3.7; P= 0.04) and metastasis-free (HR 3.5, 95% CI 1.0–12.3; P=
0.05) survival. In conclusion, invasive cribriform and/or intraductal carcinoma occurs more frequently in Gleason score 4+
4 prostate cancer patients than in Gleason score 3+ 5 and 5+ 3, and is an independent parameter for biochemical recurrence
and metastasis. Therefore, cribriform architecture has added value in risk stratification of Gleason score 8 prostate cancer
patients.
Introduction
The Gleason grading system for prostate cancer is based
on classification of histomorphological growth patterns
[1]. At the 2014 meeting of the International Society of
Urological Pathology (ISUP), consent was reached that a
Grade Group should be reported in conjunction with the
Gleason score, based on the initial work of Pierorazio
et al. which was endorsed by the World Health Organi-
zation (WHO) in 2016 [2–4]. The Grade Group system is
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comprehensive and facilitates patient communication as it
labels Gleason score 2–6 as Grade Group 1 and empha-
sizes the important distinction between Gleason score 3+
4= 7 (Grade Group 2) and 4+ 3= 7 (Grade Group 3)
prostate cancer. Grade Group 4 prostate cancer encom-
passes Gleason score 8 tumors, including Gleason score 3
+ 5, 5+ 3, and 4+ 4 [5, 6]. However, it is not yet clear
whether these three Gleason score 8 subgroups have
similar clinical outcome.
The importance of distinguishing individual prostate
cancer growth patterns is increasingly being acknowl-
edged. Gleason pattern 4 encompasses four major growth
patterns, including poorly formed, fused, glomeruloid
and cribriform glands [3]. The clinical relevance of cri-
briform architecture in prostate cancer has been well
established in recent years, as it is associated with bio-
chemical recurrence, metastasis, and disease-specific
death [7–13]. Intraductal carcinoma is characterized by
a proliferation of malignant epithelial cells with cribri-
form or solid architecture distending preexistent acini and
prostatic ducts with preservation of basal cells [3].
Although not incorporated in the Gleason score or Grade
Group, intraductal carcinoma is independently associated
with adverse oncological outcome [8, 14, 15]. The
adverse impact of invasive cribriform and intraductal
carcinoma has mainly been studied in Gleason score 3+
4 prostate cancer, as it might affect clinical decision-
making in this patient population in particular.
Some studies indicate that presence of invasive cribri-
form and intraductal carcinoma also has independent
predictive value in Gleason score 8 prostate cancer
patients [14, 16].
While the impact of cribriform architecture is well
recognized, little is known about the clinical relevance of
individual Gleason 5 growth patterns [7]. Gleason pattern
5 encompasses tumor growth in single cells, cords, and
solid fields [3]. Furthermore, presence of comedonecrosis
is considered Gleason pattern 5, whether it is present
within papillary, cribriform, or solid fields. Of notice,
recent studies have shown that comedonecrosis more
commonly occurs in intraductal carcinoma than in inva-
sive carcinoma, requiring basal cell immunohistochem-
istry for their distinction [17–19]. While Gleason score 8
prostate cancer is generally considered a high-risk disease
requiring immediate therapeutic intervention, analysis of
individual Gleason 4 and 5 growth patterns might attri-
bute to risk stratification and optimize personalized
treatment decisions. The objective of this study is to
compare the clinical characteristics and outcome of
Gleason score 3+ 5, 5+ 3, and 4+ 4 subgroups and to
investigate the impact of invasive cribriform and/or




Patients who had undergone radical prostatectomy for
prostatic adenocarcinoma from three university medical
centers in The Netherlands between 2000 and 2017 were
included in this study; 854 patients were operated at Eras-
mus MC, University Medical Center, Rotterdam; 96 at
Leiden University Medical Center (LUMC), Leiden; and
137 at Antoni van Leeuwenhoek Hospital, the Netherlands
Cancer Institute (NKI), Amsterdam. Whereas the radical
prostatectomies from Erasmus MC were consecutive, those
from LUMC and NKI were selected for presence of Glea-
son score 4+ 3 to 10 in the original pathology report. We
excluded men who had undergone hormonal, radiation, and/
or viral therapy (n= 23) prior to operation [20]. Radical
prostatectomy specimens were fixed in neutral-buffered
formalin, after which they were sectioned transversely and
embedded entirely for diagnostic purposes. All slides were
available for pathology review. This study was approved by
the institutional Medical Research Ethics Committee
(MEC-2018-1614).
Pathologic evaluation
All 1064 radical prostatectomy specimens were reviewed in
common sessions by two investigators (EH, GvL), blinded
to clinical outcome. For each specimen the following fea-
tures were recorded: Gleason score and Grade Group
according to the 2014 ISUP/2016 WHO guidelines, pT-
stage according to the American Joint Committee on Cancer
TNM 8th edition, surgical margin status, presence of
intraductal carcinoma, and percent Gleason 4 and 5 growth
patterns [3, 21]. In case of multifocality we only monitored
the characteristics of the index tumor defined as the tumor
with the highest grade, stage or volume.
The following Gleason 4 growth patterns were recog-
nized: poorly formed, fused, glomeruloid, and cribriform
glands [2, 3]. Furthermore, we distinguished small and large
cribriform gland architecture (Fig. 1a, b), since the latter is
associated with more aggressive behavior [12]. Large cri-
briform structures were defined as having a diameter more
than twice the size of adjacent benign glands. We examined
the following Gleason 5 growth patterns: single cells, cords,
and solid fields (Fig. 1c–f). Single cells and cords were
grouped for analysis. Solid fields were divided into those
with small solid nests containing 10–30 cells, and those
consisting of medium to large solid fields with more than 30
cells. In case comedonecrosis was present in invasive cri-
briform or solid fields, this was considered Gleason pat-
tern 5. Invasive cribriform Gleason pattern 4 and solid
pattern 5 either with or without comedonecrosis were
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morphologically distinguished from intraductal carcinoma
based on the following features: invasive cribriform and
solid prostate cancer had irregular borders or formed
interconnecting fields, well exceeding the outline of dis-
tended preexistent glands, or extended into periprostatic
adipose tissue, ejaculatory ducts or seminal vesicles. Intra-
ductal carcinoma was continuous with preexistent glands
lined by basal cells, or contained corpora amylacea. In case
invasive cribriform or solid carcinoma and intraductal car-
cinoma could not be differentiated by morphological criteria
alone, additional basal cell immunohistochemistry was
performed. Basal cell immunohistochemistry (34BE12) was
performed in 189/854 (22%) radical prostatectomy speci-
mens from Erasmus MC, including 14/31 (45%) Gleason
score 8 tumors with cribriform or solid architecture; no
paraffin blocks were available from the other hospitals. If
basal cells were completely absent, the lesion was classified
as either invasive cribriform Gleason pattern 4 or solid
pattern 5 carcinoma. When sporadic, scattered or con-
tinuous basal cells were identified, the lesion was con-
sidered intraductal carcinoma. Intraductal carcinoma and
tertiary patterns were not incorporated in the Gleason score
[2, 3, 22]. Minor high-grade components occupying <5% of
the tumor volume were considered as tertiary pattern. The
Grade Group concordance rate at revision was 88/135
(65%) for radical prostatectomies from NKI and 39/94
(41%) for specimens from LUMC.
Clinical follow-up
Clinical follow-up after radical prostatectomy consisted of
6 monthly, and later annual monitoring of serum prostate-
specific antigen (PSA) levels. Biochemical recurrence was
defined as PSA levels ≥0.2 ng/ml measured at two con-
secutive points in time, at least 3 months apart with unde-
tectable PSA levels after operation, or as PSA increase of
>2.0 ng/ml when serum PSA had not declined to zero after
operation. Postoperative lymph node and distant metastases
were confirmed by biopsy or multidisciplinary consensus.
Statistical analysis
Continuous variables with normal distribution were ana-
lyzed using the independent sample Student’s t test for two
groups, or one-way ANOVA for ≥3 groups. Variables
without normal distribution were analyzed using the
Fig. 1 Gleason pattern 4 and
pattern 5 tumor morphology.
a Gleason pattern 4, small
invasive cribriform structures,
15×. b Gleason pattern 4, large
invasive cribriform structures,
10×. c Gleason pattern 5, cords,
20×. d Gleason pattern 5, small
solid nests with subtle
intervening stroma, 20×.
e Gleason pattern 5, medium to
large sized solid fields, 15×.
f Gleason pattern 5,
comedonecrosis in a solid
field, 15×.
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Mann–Whitney U test for two groups, or Kruskal–Wallis
test for ≥3 groups. For comparison of categorical parameters
Pearson’s chi squared (χ2) test was used, and Fisher’s exact
test in case of small numbers (n ≤ 20). Missing PSA values
(n= 27) were imputed using the median PSA value. Bio-
chemical recurrence-free survival and metastasis-free sur-
vival were analyzed using Cox proportional hazards model
and visualized by Kaplan–Meier curves. Statistics were
performed using SPSS version 24 (IBM, Chicago, IL,
USA). Results were considered significant when the two-
sided P value was <0.05.
Results
Characteristics of Gleason score 8 prostate cancer
patients
Out of 1064 radical prostatectomy specimens, 140 (13%)
had Gleason score 8 prostate cancer. The median age of
Gleason score 8 patients was 65.3 years (interquartile range
(IQR) 61.4–68.5 years) and median serum PSA level was
10.0 ng/ml (IQR 7.2–16.0 ng/ml). Gleason scores were
distributed as follows: 76 (54%) men had Gleason score 3
+ 5, 46 (33%) Gleason score 4+ 4, and 18 (13%) Gleason
score 5+ 3. Pathologic tumor stage was T2 in 67 (48%)
men, T3a in 44 (31%), and T3b in 28 (20%). One (1%)
patient had a T4 tumor and was grouped with T3b tumors
for further analysis. Positive surgical margins were present
in 68 (49%) cases. Pelvic lymph node dissection was per-
formed in 91 (65%) men, 12 (9%) of whom had lymph node
metastasis. Median follow-up time was 68.7 months (IQR
36.7–102.8).
Clinicopathological features and outcome of
Gleason score 3+ 5, 4+ 4, and 5+ 3
The clinicopathological features of Gleason score 8 patients
stratified for Gleason score are shown in Table 1. The
median PSA level of patients with Gleason score 5+ 3
prostate cancer was 13.4 ng/ml (IQR 8.8–26.8 ng/ml), sig-
nificantly higher than for men with Gleason score 3+ 5
(10.0 ng/ml; IQR 7.4–15.0 ng/ml; P= 0.05) and Gleason
score 4+ 4 (8.9 ng/ml; IQR 6.9–16.0 ng/ml; P= 0.03).
PSA levels of Gleason score 3+ 5 and 4+ 4 were com-
parable (P= 0.45). Age, pT-stage, surgical margin status
and lymph node metastases were not significantly different
between groups. While Gleason pattern 4 constituted ≥95%
of the tumor volume in Gleason score 4+ 4 by definition, it
was present in 73/76 (96%) Gleason score 3+ 5 and 12/18
Table 1 Gleason score 8 patients






























T2 67 (48%) 41 (54%) 19 (41%) 7 (39%) 0.35
T3a 44 (31%) 19 (25%) 19 (41%) 6 (33%)
T3b/T4 29 (21%) 16 (21%) 8 (18%) 5 (28%)
Overall cribriform 87 (62%) 36 (47%) 43 (93%) 8 (44%) <0.001
Gleason pattern 4
Small cribriform 83 (59%) 33 (43%) 42 (91%) 8 (44%) <0.001
Large cribriform 38 (27%) 6 (8%) 28 (61%) 4 (22%) <0.001
Intraductal carcinoma 48 (34%) 21 (28%) 23 (50%) 4 (22%) 0.02
Gleason pattern 5
Single cells and/or cords 99 (71%) 72 (95%) 10 (22%) 17 (94%) <0.001
Small solid nests 23 (16%) 16 (21%) 1 (2%) 6 (33%) 0.003
Medium to large
solid fields
15 (11%) 4 (5%) 5 (11%) 6 (33%) 0.006
Comedonecrosis 9 (6%) 2 (3%) 7 (15%) 0 0.02
Positive surgical margins 68 (49%) 40 (53%) 20 (44%) 8 (44%) 0.58
Pelvic lymph node
dissection
91 (65%) 47 (62%) 29 (63%) 15 (83%) 0.22
Lymph node metastasis 12 (13%) 5 (11%) 4 (14%) 3 (20%) 0.54
Biochemical recurrence 68 (49%) 31 (41%) 29 (63%) 8 (44%) 0.05
Metastasis 36 (26%) 14 (18%) 18 (39%) 4 (22%) 0.04
Disease-specific death 12 (9%) 4 (5%) 7 (15%) 1 (6%) 0.17
Values denote either mean (median; IQR) or n (%).
PSA prostate-specific antigen.
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(67%) 5+ 3 tumors. The median percentage of Gleason
pattern 4 was 30% (IQR 20–35%) in 3+ 5 tumors and 18%
(IQR 0–21%) in 5+ 3 tumors (P < 0.001). Tertiary (<5%)
Gleason pattern 5 was observed in 16/46 (35%) Gleason
score 4+ 4 tumors.
Biochemical recurrence and postoperative distant
metastasis were observed in 68 (49%) and 36 (26%)
patients, respectively. Twenty-nine (63%) men with Glea-
son score 4+ 4 tumors experienced biochemical recurrence
compared to 31 (41%, P= 0.02) with Gleason score 3+ 5
and 8 (44%, P= 0.78) with 5+ 3. Biochemical recurrence-
free survival was significantly shorter for patients with
Gleason score 4+ 4 than Gleason score 3+ 5 (log rank
P= 0.02) prostate cancer. Gleason score 5+ 3 had the
lowest absolute number of events and did not significantly
differ from Gleason score 3+ 5 (log rank P= 0.82) and
Gleason score 4+ 4 (log rank P= 0.26, Fig. 2). A similar
trend was found for postoperative metastasis. Metastases
occurred in 18 (39%) men with Gleason score 4+ 4 com-
pared with 14 (18%, P= 0.01) with Gleason score 3+ 5
and 4 (22%, P= 0.20) men with Gleason score 5+ 3.
Metastasis-free survival was significantly shorter for
patients with Gleason score 4+ 4 than Gleason score 3+ 5
(log rank P= 0.006) prostate cancer. Gleason score 5+ 3
did not significantly differ from Gleason score 3+ 5 (log
rank P= 0.63) and Gleason score 4+ 4 (log rank P= 0.25).
The number of disease-specific deaths (n= 12, 9%) was too
low for subgroup analysis.
Cribriform architecture in Gleason score 8 prostate
cancer
Invasive and/or intraductal cribriform carcinoma was pre-
sent in 87 (62%) men, of whom 36 (41%) had Gleason
score 3+ 5, 43 (49%) Gleason score 4+ 4, and 8 (10%)
Gleason score 5+ 3 tumors. Of these, 83 (95%) had inva-
sive and 48 (55%) had intraductal cribriform carcinoma.
Both patterns were concurrently present in 44 (51%) men.
Invasive cribriform carcinoma only was seen in 39 (44%)
men and intraductal cribriform carcinoma only in 4 (5%)
men. Large cribriform carcinoma was present in 37 (43%)
men with cribriform architecture and was always accom-
panied by small cribriform carcinoma. Invasive and/or
intraductal cribriform carcinoma was observed more fre-
quently in Gleason score 4+ 4 than in Gleason score 3+ 5
(93% versus 47%, P < 0.001) and 5+ 3 (93% versus 44%,
P < 0.001) tumors. Large invasive cribriform carcinoma
also occurred more often in Gleason score 4+ 4 than in
3+ 5 (61% versus 8%, P < 0.001) or 5+ 3 (61% versus
22%, P < 0.001) tumors, while its appearance in Gleason
score 3+ 5 and 5+ 3 was not significantly different
(P= 0.08) in this cohort.
Gleason score 8 prostate cancer was stratified based on
presence of invasive and/or intraductal cribriform carci-
noma (Table 2). Non-organ confined disease (63% versus
34%, ≥pT3a, P= 0.003) and positive pelvic lymph nodes
(19% versus 3%, P= 0.05) were more common in patients
with cribriform architecture. Age, PSA levels, and surgical
margin status were not significantly different between
Gleason score 8 patients with or without cribriform archi-
tecture. Patients with cribriform architecture had sig-
nificantly shorter biochemical recurrence-free (log rank P=
0.001), metastasis-free (log rank P < 0.001), and disease
specific (log rank P= 0.01) survival than those without
(Fig. 3).
Histomorphology of Gleason pattern 5
Gleason pattern 5 was observed in 110 (79%) Gleason score
8 tumors. In addition to men with Gleason score 3+ 5 and
Fig. 2 Survival curves stratified for individual Gleason score. Kaplan–Meier curves of a biochemical recurrence-free survival (log rank P=
0.001), b metastasis-free survival (log rank P < 0.001), and c disease-specific survival (log rank P= 0.01) in Gleason score 8 patients stratified for
individual Gleason score.
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5+ 3, 16 (35%) men with Gleason score 4+ 4 had tertiary
Gleason pattern 5. Single cells and/or cords were present in
99/110 (90%) and solid fields in 32/110 (29%) tumors.
All Gleason 5 patterns were simultaneously present in
26 (24%) cases. Invasive and/or intraductal cribriform
carcinoma was present in 23/32 (72%) cases with solid
pattern 5 and in 36/78 (46%) cases with nonsolid pattern 5
(P= 0.02). Of interest, the nine solid field cases
without associated cribriform architecture all were of the
small nested type (Fig. 1d). Comedonecrosis was present in
nine cases, 7 (78%) of which were present in Gleason score
4+ 4 tumors. Comedonecrosis was accompanied by cri-
briform architecture in all 9/9 (100%) cases and by solid
fields in 5/9 (56%) cases. Moreover, comedonecrosis
was observed more often in patients with large cribriform
fields (7/20, 35%) than in those without (2/90, 2%,
P < 0.001).
Multivariable analysis of clinical outcome in Gleason
score 8 patients
In univariate Cox regression analysis, pT3a (hazard ratio
(HR) 2.1, 95% confidence interval (CI) 1.1–3.8, P= 0.02),
pT3b/4 (HR 4.6, 95% CI 2.5–8.5, P < 0.001), Gleason score
4+ 4 (HR 1.9, 95% CI 1.1–3.1, P= 0.02), positive lymph
nodes at time of operation (HR 11.8, 95% CI 5.6–25.2, P <
0.001), and overall presence of invasive and/or intraductal
cribriform carcinoma (HR 2.4, 95% CI 1.4–4.1, P= 0.003)
were significantly associated with shorter biochemical
recurrence-free survival, while age (P= 0.18), PSA level
(P= 0.43), Gleason score 5+ 3 (P= 0.78) and surgical
margin status (P= 0.21) were not (Table 3). In multi-
variable analysis, pT3b/4-stage (HR 4.4, 95% CI 2.1–9.3,
P < 0.001), positive lymph nodes (HR 9.9, 95% CI
4.2–23.5, P < 0.001), and overall cribriform architecture
(HR 2.0, 95% CI 1.0–3.7, P= 0.04) had independent pre-
dictive value for biochemical recurrence-free survival, while
Gleason score 4+ 4 (HR 1.7, 95% CI 1.0–2.9, P= 0.07)
did not meet conventional measures of significance in this
cohort. In case individual cribriform growth patterns were
included in multivariable analysis instead of overall cribri-
form architecture, large invasive cribriform carcinoma (HR
2.0, 95% CI 1.0–4.1, P= 0.05) had independent predictive
value for biochemical recurrence-free survival, whereas
intraductal cribriform carcinoma (HR 1.3, 95% CI 0.8–3.5,
P= 0.4) and small invasive cribriform carcinoma (HR 1.6,
95% CI 0.8–3.5, P= 0.2) did not (data not shown).
Similar trends were observed for metastasis as pT3a (HR
2.7, 95% CI 1.2–6.2, P= 0.02), Gleason score 4+ 4 (HR
3.8, 95% CI 1.8–8.1, P= 0.001), positive lymph nodes
(HR 11.5, 95% CI 5.2–25.9, P < 0.001), and overall cri-
briform architecture (HR 6.7, 95% CI 2.0–21.9, P= 0.002)
were significantly associated with shorter metastasis-free
survival, whereas age (P= 0.80), PSA level (P= 0.96),
pT3b/4 (P= 0.06), Gleason score 5+ 3 (P= 0.85), and
positive surgical margins (P= 0.95) were not (Table 4). In
multivariable analysis, Gleason score 4+ 4 (HR 2.4, 95%
CI 1.0–5.9, P= 0.05), positive lymph nodes (HR 15.0, 95%
CI 5.6–40.0, P < 0.001), and overall cribriform architecture
(HR 3.5, 95% CI 1.0–12.3, P= 0.05) had independent
predictive value for metastasis-free survival. Due to the low
number of events and risk of model overfitting we were not
able to include individual cribriform or Gleason 5 growth
patterns in multivariable analysis.
Discussion
Our study demonstrates that among Gleason score 8 pros-
tate cancer patients on radical prostatectomy, biochemical
recurrence and metastases occur more often in Gleason




















T2 35 (66%) 32 (37%) 0.003
T3a 10 (19%) 34 (39%)
T3b/T4 8 (15%) 21 (24%)
Gleason pattern 4 45 (85%) 86 (99%) <0.001
Small cribriform 0 83 (95%) <0.001
Large cribriform 0 38 (44%) <0.001
Intraductal carcinoma 0 48 (55%) <0.001
Gleason pattern 5 50 (94%) 60 (69%) <0.001
Single cells and/
or cords
48 (91%) 51 (59%) <0.001
Small solid nests 10 (19%) 13 (15%) 0.54
Medium to large
solid fields
0 15 (17%) <0.001
Comedonecrosis 0 9 (10%) 0.02
Positive surgical
margins
25 (47%) 43 (49%) 0.80
Pelvic lymph node
dissection
32 (60%) 59 (68%) 0.37
Lymph node
metastasis
1 (3%) 11 (19%) 0.05
Biochemical recurrence 16 (30%) 52 (60%) 0.001
Metastasis 4 (8%) 32 (37%) <0.001
Disease-specific death 0 12 (14%) 0.004
Values denote either mean (median; IQR) or n (%).
PSA prostate-specific antigen.
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score 4+ 4 than in Gleason score 3+ 5 or 5+ 3 tumors.
Invasive and/or intraductal cribriform carcinoma was
observed in 62% of tumors and was associated with adverse
pathological features and clinical outcome. Cribriform
architecture occurred more frequently in men with Gleason
score 4+ 4 (93%) than in those with Gleason score 3+ 5
(47%) and 5+ 3 (44%). In multivariable analysis, cribri-
form architecture was an independent parameter for bio-
chemical recurrence- and metastasis-free survival, while
Gleason score was not. Therefore, cribriform architecture
also has important value for risk stratification among
Gleason score 8 prostate cancer patients.
Since the introduction of Grade Groups several reports
have analyzed the clinical outcome of Gleason score 3+ 5,
4+ 4, and 5+ 3 prostate cancer [4]. Some of these studies
found that men with Gleason score 3+ 5 at radical pros-
tatectomy had reduced risk of biochemical recurrence
among Gleason score 8 patients [23, 24]. Others did not find
Fig. 3 Survival curves stratified for cribriform architecture.
Kaplan–Meier curves of a biochemical recurrence-free survival (log
rank P= 0.001), b metastasis-free survival (log rank P < 0.001), and
c disease-specific survival (log rank P= 0.01) in Gleason score 8
patients with invasive and/or intraductal cribriform carcinoma (CR/
IDC+) and without invasive and/or intraductal cribriform carcinoma
(CR/IDC−).
Table 3 Cox regression analysis for biochemical recurrence-free
survival in Gleason score 8 patients.
Univariate Multivariable
HRa 95% CI P value HR 95% CI P value
Age (years) 1.0 0.9–1.0 0.18 1.0 0.9–1.0 0.05
PSA (ng/ml) 1.0 1.0–1.0 0.43 1.0 1.0–1.0 0.23
pT-stage
T2 ref ref
T3a 2.1 1.1–3.8 0.02 1.8 1.0–3.4 0.06
T3b/T4 4.6 2.5–8.5 <0.001 4.4 2.1–9.3 <0.001
Gleason score
3+ 5 ref ref
4+ 4 1.9 1.1–3.1 0.02 1.7 1.0–2.9 0.07
5+ 3 1.1 0.5–2.4 0.78 1.5 0.6–3.6 0.37
Positive surgical
margins
1.4 0.8–2.2 0.21 0.8 0.5–1.5 0.55
Pelvic lymph
node metastasis
11.8 5.6–25.2 <0.001 9.9 4.2–23.5 <0.001
Cribriform
architecture
2.4 1.4–4.1 0.003 2.0 1.0–3.7 0.04
CI confidence interval.
aHR= hazard ratio.
Table 4 Cox regression analysis for metastasis-free survival in
Gleason score 8 patients.
Univariate Multivariable
HRa 95% CI P value HR 95% CI P value
Age (years) 1.0 0.9–1.1 0.80 1.0 0.9–1.1 0.52
PSA (ng/ml) 1.0 1.0–1.0 0.96 1.0 0.9–1.0 0.50
pT-stage
T2 ref ref
T3a 2.7 1.2–6.2 0.02 2.5 1.0–6.7 0.06
T3b/T4 2.4 1.0–6.0 0.06 1.3 0.4–3.8 0.67
Gleason score
3+ 5 ref ref
4+ 4 3.8 1.8–8.1 0.001 2.4 1.0–5.9 0.05




1.0 0.5–2.0 0.95 1.1 0.5–2.4 0.84
Pelvic lymph
node metastasis
11.5 5.2–25.9 <0.001 15.0 5.6–40.0 <0.001
Cribriform
architecture
6.7 2.0–21.9 0.002 3.5 1.0–12.3 0.05
CI confidence interval.
aHR= hazard ratio.
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a difference among Gleason score 8 subgroups or concluded
that men with primary Gleason pattern 5 had worse out-
come [16, 25–28]. This variability of results might be
explained by the use of different specimen types and clin-
ical outcome measures [29]. Furthermore, Gleason score 8
is relatively uncommon, hampering statistical analysis on
large numbers of patients or resulting in clustering of
Gleason score 5+ 3 and 5+ 3 tumors [28, 30]. Finally,
from a morphologically point of view, Gleason score 8
prostate cancer is a very heterogeneous disease including
highly variable quantities of Gleason 3, 4, and 5 growth
patterns. This heterogeneity might lead to significant inter-
observer variability in tumor grading. For instance, Shah
et al. only found fair interobserver reproducibility for
Gleason pattern 5 assignment among 16 international expert
genitourinary pathologists [31]. Upon rereview of 40
archival cases with Gleason score 5+ 3 prostate cancer,
Kryvenko et al. assigned the same score in only 4 (10%)
specimens, but upgraded 57.5% and downgraded 17.5% of
cases [32].
Many studies demonstrated worse clinical outcome for
patients with cribriform architecture [7–11]. Most of these
studies investigated cribriform architecture in intermediate
grade prostate cancer, while the impact of cribriform
architecture in Gleason score ≥4+ 3 is less well established.
In Gleason score 7–10 prostate cancer biopsy patients,
presence of cribriform architecture has been associated with
advanced pathological stage and worse disease-specific
survival compared with those with cribriform-negative
biopsies [14, 33]. Harding-Jackson et al. found cribriform
architecture, but not Gleason score, to have independent
predictive value for cancer-specific survival in Gleason
score 8 patients [16]. In the current study, we confirmed that
cribriform architecture had strong discriminative value,
even in aggressive Gleason score 8 prostate cancer. Both
overall invasive cribriform and/or intraductal carcinoma as
well as its more aggressive large cribriform variant were
significantly more often observed in Gleason score 4+ 4,
than 3+ 5 and 5+ 3 disease. Since its association with
adverse outcome, the high frequency of cribriform archi-
tecture might well explain the worse outcome of Gleason
score 4+ 4 prostate cancer compared with those with 3+ 5
in our study, while the low number of 5+ 3 patients ham-
pered powerful statistical analysis. Of interest, however, is
that in multivariable analysis not only cribriform archi-
tecture but also Gleason score 4+ 4 had independent
prognostic value for metastasis-free survival. A similar
trend was observed for biochemical recurrence-free survival
although the predictive value of Gleason score 4+ 4 did not
reach conventional measures of significance (P= 0.07).
This implicates that other grading factors apart from cri-
briform architecture contribute to the worse outcome in
Gleason score 4+ 4 patients. A possible explanation could
be that Gleason score 4+ 4 disease has the lowest percent
of Gleason 3 growth pattern, which is by definition present
in less than 5% of the tumor volume. In 3+ 5 disease,
percent Gleason pattern 3 theoretically varies from 50% to
95%, while it occupies 5% to 50% in Gleason score 5+ 3
tumors. Some groups have shown independent prognostic
value for percent Gleason pattern 4 and 5, which out-
performed Gleason score [34]. The inverse could well be
true for percent Gleason pattern 3; if a tumor still has the
biological capacity to mature into well-delineated glandular
structures it is associated with better outcome.
Little is known about the predictive value of individual
Gleason grade 5 growth patterns, which have been reported
as either single cells, cords, small solid cylinders, solid
fields, and presence of comedonecrosis [3]. Single cells and/
or cords are the most common Gleason pattern 5 [35, 36].
Flood et al. found that presence of solid fields and number
of different Gleason 5 growth patterns were associated with
shorter biochemical recurrence-free survival in Gleason
score 9–10 prostatectomies [35]. Compared with other
Gleason 5 patterns, comedonecrosis was associated with
non-organ confined disease and biochemical recurrence
[19, 37]. While individual Gleason 4 growth patterns have
increasingly been subject to clinicopathological analysis,
information on the clinical relevance of Gleason 5 patterns
is still scarce. Our group recently performed in-depth three-
dimensional visualization of prostate adenocarcinoma
architectural growth patterns and revealed two separate
morphological groups [38]. The first group consists of a
tubular network in which the vast majority if not all tumor
cells are in direct contact with surrounding stroma. This
group encompasses the morphological continuum of Glea-
son pattern 3, poorly formed and fused pattern 4, and single
cells and cords pattern 5. The second group has contiguous
epithelial proliferations in which the majority of tumor cells
are not in contact with surrounding stroma and consists
of cribriform pattern 4 and solid pattern 5 with or without
comedonecrosis. Our current finding that solid fields mostly
coexisted with cribriform structures is reflective of
this continuum. In the current study, we distinguished
between small nested cylinders consisting up to 30 tumor
cells and larger solid fields. While the latter was continuous
with cribriform growth, small nested cylinders were not.
This suggests that both have different biological and pos-
sibly clinical relevance. However, larger studies are
required to perform statistical analysis on the clinical rele-
vance of individual Gleason 5 growth patterns.
Strong points of this study are the detailed histological
review of radical prostatectomy specimens and the classi-
fication of cribriform architecture with the use of strict
morphological criteria and additional immunohistochem-
istry. The study is limited by the retrospective study design.
The inclusion of high-grade samples from two participating
E. Hollemans et al.
centers could have resulted in a selection bias. Furthermore,
the relatively short follow-up of 59 months and limited
number of patients restricted robust statistical analysis.
In conclusion, Gleason score 8 is a heterogeneous group
of prostate cancers. Although clinicopathological char-
acteristics of Gleason score 3+ 5, 4+ 4, and 5+ 3 are
mostly similar, Gleason score 4+ 4 patients have a higher
risk of adverse events. Cribriform architecture is an inde-
pendent predictor for metastasis-free survival and has better
discriminative value for clinicopathological outcome than
Gleason score. Therefore, reporting cribriform architecture
might add value in risk stratification of Gleason score 8
prostate cancer patients.
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